Bifenacin is used for hepatitis-induced elevation of GTPase 150 U/L, which can generally be reduced to normal in about 1 week. However, it should not be stopped immediately and the rebound of transaminases should be watched. Bifendione is an adjunctive therapy for hepatitis, mainly used for the treatment of acute and chronic viral hepatitis, alcoholic liver disease, immune liver disease, and drug-related liver injury. It can rapidly reduce glutamic aminotransferase, but has no therapeutic effect on glutamic aminotransferase and glutamyl transpeptidase, and cannot reverse the damage of liver cells. Therefore, bifendione needs to be used in combination with other liver-protective drugs. The therapeutic effect of this drug is related to the type of hepatitis and the severity of the disease. If glutathione has reached 150 U/L and there is more severe liver damage, the patient takes bifenthix for treatment for about 1 week before it can be brought down to normal. In addition, because long-term or overdose of bifendione can aggravate liver damage, patients should test their liver function during the course of taking the drug and switch to other medication if necessary.